Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine vs articaine vs mepivacaine for pulpal anesthesia in maxillary molars with irreversible pulpitis
IRCT20220226054132N1Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lidocaine, articaine and mepivacaine in irreversible pulpitis (3 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Anesthesia success. Started Apr 2022; status: completed.
02
Drugs
lidocainearticainemepivacaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on IRCT20220226054132N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220226054132N1.